10,399 34,870 29,588
Loss from operations (8,858) (10,399) (34,870) (29,588)
Interest and other income, net 193 860 862 2,658
Net loss $(8,665) $(9,539) $(34,008) $(26,930)
Net loss per share - basic and
diluted $(0.37) $(0.42) $(1.48) $(1.35)
Weighted-average common shares
outstanding used in per share
calculation 23,211 22,656 23,056 19,999
(1) Includes the following stock-
based compensation charges:
Research and development $369 $294 $1,150 $1,030
General and administrative $594 $490 $1,939 $1,322
XTENT, INC.
(a development stage company)
Condensed Balance Sheets
(unaudited, in thousands)
September 30, December 31,
2008 2007
Cash, cash equivalents and short term
investments $25,585 $57,760
Working capital 23,369 54,581
Total assets 30,856 62,415
Deficit accumulated during the
development stage (126,868) (92,860)
Total stockholders' equity 27,839 58,331
'/>"/>SOURCE XTENT, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine news :1.
XTENT Announces Second Quarter 2008 Financial Results and Business Progress2.
XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors3.
XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention4.
XTENT to Present at Cowen and Companys 28th Annual Health Care Conference5.
XTENT Announces 2007 Financial Results6.
New study shows extent of harmful human influences on global ecosystems7.
XTENT Announces 2007 Financial Results Conference Call8.
XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe9.
XTENT Announces Third Quarter 2007 Financial Results10.
ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2008 and to Provide a Business Update11.
Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008